课题基金 / 基金详情

Monosaccharide Analog/Sialic acid Metabolism & Apoptosis

Monosaccharide Analog/Sialic acid Metabolism & Apoptosis
单糖类似物/唾液酸代谢
批准号:
6966649
负责人:
KEVIN J YAREMA
金额:
$31.98万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-09-01 至 2009-06-30

项目摘要

项目成果

KEVIN J YAREMA的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):外源性单糖补充糖基化途径对从罕见先天性疾病(CDGs)到癌症等人类疾病具有潜在的治疗价值。特别是,调节细胞表面唾液酸显示的n -乙酰甘露糖胺(ManNAc)类似物是解决在各种癌症中发现的糖基化缺陷的有希望的候选者。糖类似物从目前的实验室工具到临床应用的转变最近得到了我们实验室最近的发现的推动,糖类似物诱导的毒性是通过用羟基保护基团修饰单糖来改善其药理特性引起的,这是由于细胞凋亡。这一观察结果,结合细胞凋亡刺激剂作为控制癌症的关键靶点的出现,支持加强研究唾液酸与细胞凋亡之间联系的努力:具体目标#1是表征ManNAc类似物在人类癌细胞凋亡中的作用,重点是n -酰基“R1”组的作用。这一目标将通过(A)测试类似物对O-GlcNAc蛋白修饰的影响;(B)逐步评估执行细胞凋亡的各种细胞通路对类似物的反应;(C)测试类似物对细胞“生物合成机制”的影响,细胞利用类似物构建一组参与凋亡的唾液糖缀合物,包括Fas、TNFalphaR2、IGF和CD43;(D)评估通过唾液酸生物合成途径抑制代谢通量是否是引起类似物诱导的细胞凋亡的原因或下游反应。Aim #1中概述的一系列实验旨在全面评估甘露聚糖类似物对唾液酸代谢的影响,并将这些反应与细胞凋亡联系起来。这些化合物还通过o -羟基“R2”基团修饰引起细胞范围的反应。在这个项目中,r2组的细胞反应(在摄入时将短链脂肪酸(SCFA)输送到细胞)将在Aim #2中进行测试:特定的Aim #2是通过(a)分析细胞对类似物提供的SCFA的反应,(B)表征SCFA“载体”分子的作用,(C)分析神经酰胺和神经节苷脂在类似物处理的细胞中的代谢,以及(D)测试r2组的代谢“携带”来表征r2组在细胞凋亡中的作用。
英文摘要
DESCRIPTION (provided by applicant): The supplementation of glycosylation pathways with exogenously-supplied monosaccharide has potential therapeutic value for human diseases ranging from rare congenital disorders (CDGs) to cancer. In particular, N-acetylmannosamine (ManNAc) analogs that modulate cell surface sialic acid display are promising candidates for addressing glycosylation defects found in a wide range of cancers. The transition of sugar analogs from their current status as laboratory tools to clinical applications has recently been given a boost by our laboratory's recent finding that sugar analog-induced toxicity observed upon modification of monosaccharide with hydroxyl-protecting groups designed to improve their pharmacological properties is due to apoptosis. This observation, combined with the emergence of apoptosis stimulators as key targets for the control of cancer, support enhanced efforts to investigate the connections between sialic acid and apoptosis: Specific Aim #1 is to characterize the role of ManNAc analogs in apoptosis in human cancer cells, with a focus on the effects of the N-acyl "R1" group. This goal will be pursued by (A) testing the impact of the analogs on O-GlcNAc protein modification; (B) performing a step by step evaluation of the response of the various cellular pathways that execute apoptosis to analogs; (C) testing the effects of analogs on the 'biosynthetic machinery' used by cells to construct a set of the sialoglycoconjugates involved in apoptosis that include Fas, TNFalphaR2, IGF, and CD43; and (D) evaluating whether inhibition of metabolic flux through the sialic acid biosynthetic pathway is the cause, or a downstream response, to analog-induced apoptosis. The set of experiments outlined in Aim #1 are designed to comprehensively evaluate the effects of ManNAc analogs on sialic acid metabolism and link these responses to apoptosis. These compounds also elicit cell-wide responses by virtue of O-hydroxyl "R2" group modifications. In this project, cellular responses of R2-groups, which deliver short chain fatty acids (SCFAs) to a cell upon intake, will be tested in Aim #2: Specific Aim #2 is to characterize the role of R2-groups in apoptosis by (A) analyzing cellular response to analog-supplied SCFAs, (B) characterizing the effects of the SCFA 'carrier' molecule, (C) analyzing ceramide and ganglioside metabolism in analog-treated cells and (D) testing metabolic 'carry-through' of R2-groups.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
AGX1/2 inhibitors as key modulators of the hexosamine biosynthetic pathway
  • 批准号:
    8977496
  • 项目类别:
  • 资助金额:
    $17.62万
  • 财政年份:
    2014
  • 负责人:
    KEVIN J YAREMA
  • 依托单位:
Monosaccharide Analogs, Sialic Acid Metabolism and Apoptosis
  • 批准号:
    7844508
  • 项目类别:
  • 资助金额:
    $2.16万
  • 财政年份:
    2009
  • 负责人:
    KEVIN J YAREMA
  • 依托单位:
Engineering a Carbohydrate-Biomaterial Interface for Control of Wnt Signaling and
  • 批准号:
    7393168
  • 项目类别:
  • 资助金额:
    $35.98万
  • 财政年份:
    2007
  • 负责人:
    KEVIN J YAREMA
  • 依托单位:
Engineering a Carbohydrate-Biomaterial Interface for Control of Wnt Signaling and
  • 批准号:
    7211956
  • 项目类别:
  • 资助金额:
    $32.45万
  • 财政年份:
    2007
  • 负责人:
    KEVIN J YAREMA
  • 依托单位:
国内基金
海外基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2020
  • 负责人:
    郑绪阳
  • 依托单位:
去乙酰化酶SIRT1在前体mRNA可变剪切中的作用及其生理病理效应研究
  • 批准号:
    31970691
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2019
  • 负责人:
    张胜萍
  • 依托单位:
TM9SF4调控非小细胞肺癌细胞凋亡机制研究
  • 批准号:
    31900527
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2019
  • 负责人:
    孙磊
  • 依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2017
  • 负责人:
    卫高菲
  • 依托单位: